Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype-selective Nav1.7 inhibitor (Ki: 0.79 nM, Kd: 0.38 nM for hNav1.7) for the treatment of chronic pain.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 3,170.00 | |
50 mg | 10-14 weeks | $ 4,180.00 | |
100 mg | 10-14 weeks | $ 5,800.00 |
Description | GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype-selective Nav1.7 inhibitor (Ki: 0.79 nM, Kd: 0.38 nM for hNav1.7) for the treatment of chronic pain. |
Targets&IC50 | Nav1.6 (human):29 nM (ki), Nav1.2 (human):12 nM (ki), Nav1.7 (human): kd:0.38 nM , Nav1.7 (human):ki:0.79 nM |
In vitro | Site-directed mutagenesis is critical for the isoform selectivity profile of GNE-616. |
In vivo | GNE-616 shows robust activity in a Nav1.7-dependent inherited erythromelalgia (IEM) PK/PD model. |
Molecular Weight | 537.53 |
Formula | C24H23F4N5O3S |
CAS No. | 2349371-81-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GNE-616 2349371-81-7 Others GNE 616 GNE616 inhibitor inhibit